This bill directs the Secretary of the Interior to collaborate with Indian Tribes within one year of enactment to identify culturally significant "Native American seeds" and support tribal seed banks, traditional agriculture systems, and seed protection efforts. It requires the Secretary to safeguard any culturally sensitive or confidential information shared by Tribes under this Act, prohibiting its disclosure. The bill does not authorize new funding, relying instead on existing appropriations for implementation. It directly affects Indian Tribes by empowering them to manage and protect their traditional seed resources under federal guidance.
The Back the Blue Act of 2025 creates new federal criminal offenses for killing or assaulting law enforcement officers, judges, and certain public safety personnel (including firefighters and first responders) while they are on duty or because of their official status. It increases penalties for these crimes, including minimum 10-year prison terms for killing officers and longer sentences for assaults causing serious injury, with the death penalty possible for killings. The bill also adds a "flight to avoid prosecution" provision for those fleeing to evade charges for killing officers, expands law enforcement officers' rights to carry firearms in certain circumstances, and limits federal habeas corpus relief for individuals convicted of killing law enforcement officers. This legislation directly affects law enforcement officers, judges, and public safety personnel, as well as individuals who commit violence against them.
HR 6466, the Forced Abortion Prevention and Accountability Act, prohibits non-consensual administration of abortion drugs (like mifepristone or misoprostol) to pregnant women without their informed consent. It criminalizes this act with penalties up to 25 years in prison and allows victims to sue for triple damages, psychological/physical injury compensation, and attorney fees. The bill directly affects pregnant women who might face coerced procedures and medical providers or others who administer such drugs without consent. Key provisions include criminal penalties for the act itself, enhanced penalties for serious injury or death, and a civil remedy framework for victims seeking compensation.
This Senate resolution (SRES 525) condemns the Iranian government's ongoing, state-sponsored persecution of the Baha'i minority, citing decades of systemic abuses including executions, job dismissals, education bans, and property confiscations. It references UN reports and Human Rights Watch findings documenting Iran's violation of international human rights treaties, such as the Universal Declaration of Human Rights and the International Covenant on Civil and Political Rights. The resolution calls on Iran to immediately release imprisoned Baha'is, end discriminatory policies restricting their education and employment, and cease hate propaganda, while urging the U.S. President and Secretary of State to impose sanctions on Iranian officials responsible for these abuses.
This bill increases the tax exclusion for capital gains when selling a primary residence. It doubles the exclusion amount from $250,000 (for single filers) to $500,000 and from $500,000 (for married couples) to $1,000,000. The bill also adds an inflation adjustment for amounts after 2025, tying future increases to the cost-of-living adjustment. It directly affects homeowners who sell their primary residence and would otherwise owe tax on profits exceeding the previous limits. The changes apply to sales after the bill's enactment date.
The LAB Personnel Act of 2025 (S 3334) protects the laboratory workforce at the Drug Enforcement Administration (DEA) from hiring freezes or workforce reductions caused by budget cuts or fund reprogramming. It directly affects DEA forensic lab staff, including forensic chemists, fingerprint specialists, digital forensic examiners, and other defined roles in DEA forensic laboratories. The bill mandates that these positions be exempt from reductions related to spending constraints, while clarifying that it does not prevent the Attorney General from managing staff under existing misconduct or performance procedures. This is a concrete policy change to maintain staffing levels in DEA forensic operations.
HR 6372, the D.C. Shield Law Repeal Act, repeals the Human Rights Sanctuary Amendment Act of 2022 (D.C. Law 24-257), which had modified District of Columbia protections for certain immigrant residents. The bill restores the previous legal framework that existed before the 2022 amendment took effect. This directly affects D.C. law and its implementation regarding immigrant rights within the District.
This bill requires the Veterans Health Administration to expand its existing informed consent directive (currently covering long-term opioid therapy) to include written consent for five additional medication categories: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. It directly affects Veterans receiving VA care for these specific medications, mandating that providers obtain written informed consent before prescribing them. The key mechanism is updating VA Directive 1005 to explicitly apply to these new medication types, ensuring consistent consent processes across VA treatment. This change applies only to VA healthcare settings, not to civilian medical practices.
S 1228 amends the Public Lands Corps Act of 1993 to change cost-sharing requirements for conservation projects run by qualified youth or conservation corps on public lands. It increases the federal government's required cost-share from 75% to 90% and decreases the non-federal partner's share from 25% to 10%. This directly affects conservation corps and their partners by reducing their financial burden for projects on public lands. The bill makes no other changes to the Act's provisions.
HR 4313, the Hospital Inpatient Services Modernization Act, extends Medicare's waiver allowing acute hospital care at home until 2030 (previously expiring in 2025). It requires the Secretary of Health and Human Services to conduct a detailed study by September 2028 comparing home-based hospital care to traditional inpatient care. The study must analyze quality metrics (like readmission rates and patient outcomes), costs, staffing patterns, and patient demographics - including racial, ethnic, and socioeconomic data - across participating and non-participating hospitals. This bill directly affects Medicare beneficiaries receiving home-based care and hospitals operating under the waiver program.
HR 3806, the New World Screwworm Preparedness Act of 2025, requires the U.S. Department of Agriculture to conduct a study on the nation's readiness to prevent and respond to New World screwworm (NWS) infestations. The study must assess current threats, sterile insect production capabilities, surveillance systems, emergency response plans, research needs, and international cooperation, with input from livestock producers, wildlife agencies, and scientists. The Secretary of Agriculture must submit a report to Congress within six months detailing findings and recommendations for improving preparedness. This bill directly affects agricultural stakeholders and wildlife management by mandating a review of existing capabilities, not by changing current policy.
Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research. The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)
